DEFINITIVE PROXY

Company

CNS Pharmaceuticals, Inc.

Filed

August 14, 2023

Period of Report

September 14, 2023

Accession Number

0001683168-23-005773

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →